Bioethics consultation and patient advocacy organizations: Expanding the dialogue about professional conflicts of interest

Cambridge Quarterly of Healthcare Ethics

Volumn 16, Issue 1, 2007, Pages 74-81

  Yarborough, Mark ^a   Sharp, Richard R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOETHICS; CONFLICT OF INTEREST; ETHICS; HUMAN; PATIENT ADVOCACY; PATIENT REFERRAL; PHYSICIAN ATTITUDE; REVIEW;

BIOETHICS; CONFLICT OF INTEREST; HUMANS; PATIENT ADVOCACY; PHYSICIAN'S ROLE; REFERRAL AND CONSULTATION;

EID: 33947384955     PISSN: 09631801     EISSN: 14692147     Source Type: Journal    
DOI: 10.1017/S0963180107070089     Document Type: Review

References (25)

1. Scofield GR. Ethics consultation: The least dangerous profession? Cambridge Quarterly of Healthcare Ethics 1993;2(4):417-26.
2. Turner L. The greening of bioethics: Corporate funding of bioethics research. Cambridge Quarterly of Healthcare Ethics 1998;7(3):326-8;
3. Elliott C. Pharma buys a conscience. American Prospect 2001;12(17):16-20;
4. Stolberg SG. Bioethicists find themselves the ones being scrutinized. New York Times 2001 Aug 2:A1;
5. Turner L. Bioethic$ Inc. Nature Biotechnology 2004;22(8):947-8;
6. DeVries R. Businesses are buying the ethics they want. Washington Post 2004 Feb 8:B2;
7. Elliott C. The soul of a new machine: Bioethicists in the bureaucracy. Cambridge Quarterly of Healthcare Ethics 2005;14(4):379-84.
8. See note 2, Elliott 2001.
9. See note 2, Turner 2004.
10. Brody B, Dubler N, Blustein J, Caplan A, Kahn JP, Kass N, et al. Bioethics consultation in the private sector. The Hastings Center Report 2002;32(3):14-20.
11. Sharpe VA. Science, bioethics, and the public interest: On the need for transparency. Hastings Center Report 2002;32(3):23-6;
12. Youngner SJ, Arnold R. Who will watch the watchers? The Hastings Center Report 2002;32(3):21-2.
13. Baker R. A draft model aggregated code of ethics for bioethicists. American Journal of Bioethics 2005;5(5):33-41;
14. MacDonald C. Will the "secular priests" of bioethics work among the sinners? The American Journal of Bioethics 2003;3(2):W36-9;
15. Parsi K. Bioethics consultation in the private sector: What is an appropriate model. HEC Forum 2005;17(2):135-45.
16. See note 7, Parsi 2005:137.
17. See note 2, Elliott 2001.
18. 1-Antitrypsin (AAT) Deficiency. American Journal of Respiratory and Critical Care Medicine 2003;168:818-900.
19. 1-Antitrypsin Deficiency Task Force 2003.
20. 1-Antitrypsin Deficiency Task Force 2003.
21. Sharp RR, de Serres F, Newman L, Sandhaus RA, Walsh JW, Hood E, Harry GJ. Environmental, occupational, and genetic risk factors for alpha-1 antitrypsin deficiency. Environmental Health Perspectives 2003;111:1749-52. We have never accepted any honoraria or consultant fees for our work with the Foundation. However, we are reimbursed for our travel, lodging, meals, and other incidental expenses associated with work on its behalf. In addition, we each have received $25,000 research grants from the Foundation. One of the ethics centers with which one of us is affiliated also received $2,500 from the Foundation to support a conference on ethics and genetics.
22. Beyond Science. Alpha-1-to-One; Fall 2003:10-1.
23. DeVries RG, Bosk CL. The bioethics of business: Rethinking the relationship between bioethics consultants and corporate clients. The Hastings Center Report 2004;34(5):28-32.
24. The following recommendations were developed by the authors independently from other extant recommendations, but readers will note similarities between some of our recommendations and those found in the ASBH/SLME Task Force (see note 5, Brody 2002).
25. Dresser R. When Science Offers Salvation: Patient Advocacy and Research Ethics. New York: Oxford University Press; 2001.